Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

1. A method for treating a bacterial infection or a viral infection comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor to a subject in need thereof, wherein said tyrosine kinase inhibitor comprises a compound according to the formula:

wherein:

R 1 is 4-pyrazinyl, 1-methyl-IH-pyrrolyl, amino-, or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated, or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen;

R 2 and R 3 are each independently of the other hydrogen or lower alkyl, one or two of the radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each nitro, fluoro-substituted lower alkoxy or a radical of the formula

—N(R 9 )—C(═X)—(Y) n —R 10 ;

wherein:

R 9 is hydrogen or lower alkyl;

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino, or O-lower alkyl-hydroximino;

Y is oxygen or the group NH,

n is 0 or 1; and

R 10 is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic, or hetero-cyclicaliphatic radical;

and the remaining radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified, or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy;

or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug, or derivative thereof, or the metabolite structure

wherein said bacterial infection is caused by Mycobacterium tuberculosis, Pseudomonas, Chlamydia, Helicobacter pylori, Listeria monocytogenes , or Shigella flexneri.

2. The method according to claim 1 , wherein said tyrosine kinase inhibitor comprises a compound according to the formula of claim 1 wherein:

R 1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino-, or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated by one or two lower alkyl radicals or acylated by lower alkanoyl or by benzoyl, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen;

R 2 and R 3 are each independently of the other hydrogen or lower alkyl, one or two of the radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each nitro, fluoro-substituted lower alkoxy or a radical of the formula

—N(R 9 )—C(═X)—(Y) n —R 10 ;

wherein:

R 9 is hydrogen or lower alkyl;

X is oxo, thio, imino, N-lower alkyl-imino, hydroximino, or O-lower alkyl-hydroximino;

Y is oxygen or the group NH;

n is 0 or 1; and

R 10 is an aliphatic hydrocarbon radical having 5-22 carbon atoms, a phenyl or naphthyl radical each of which is unsubstituted or substituted by cyano, lower alkyl, hydroxyl-lower alkyl, amino-lower alkyl, (4-methyl-piperazinyl)-lower alkyl, trifluoromethyl, hydroxy, lower alkoxy, lower alkanoyloxy, halogen, amino, lower alkylamino, di-lower alkylamino, lower alkanoylamino, benzolylamino, carboxy or by lower alkoxycarbonyl, or phenyl-lower alkyl wherein the phenyl radical is unsubstituted or substituted as indicated above, a cycloalkyl or cycloalkenyl radical having up to 30 carbon atoms, cycloalkyl-lower alkyl or cycloalkenyl-lower alkyl each having up to 30 carbon atoms in the cycloalkyl or cycloalkenyl moiety, a monocyclic radical having 5 or 6 ring members and 1-3 ring hetero atoms selected from nitrogen, oxygen, and sulfur, to which radical one or two benzene radicals may be fused, or lower alkyl substituted by such a monocyclic radical;

and the remaining radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by amino, lower alkylamino, di-lower alkylamino, piperazinyl, piperidinyl, pyrrolidinyl, or by morpholinyl, or lower alkanoyl, trifluoromethyl, hydroxy, lower alkoxy, lower alkanoyloxy, halogen, amino, lower alkylamino, di-lower alkylamino, lower alkanoylamino, benzoylamino, carboxy, or lower alkoxycarbonyl;

or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug, or derivative thereof, or metabolite structure

3. A method for treating a bacterial infection or a viral infection comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor to a subject in need thereof, wherein said tyrosine kinase inhibitor comprises a compound according to the formula:

or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug, or derivative thereof, or metabolite structure

wherein said bacterial infection is caused by Mycobacterium tuberculosis, Pseudomonas, Chlamydia, Helicobacter pylori, Listeria monocytogenes , or Shigella flexneri.

4. The method according to claim 1 , wherein said tyrosine kinase inhibitor comprises a derivative according to the formula:

or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug, or derivative thereof, or metabolite structure

5. The method of claim 1 , wherein the bacterial infection is caused by Mycobacterium tuberculosis, Pseudomonas or Chlamydia , and the viral infection is causes by a polyoma, HIV, Poxviridae, Orthomyxoviridae or Hepadnaviridae virus.

6. The method of claim 1 , wherein said tyrosine kinase inhibitor inhibits viral replication.

7. The method of claim 1 , wherein said tyrosine kinase inhibitor inhibits at least one Abl-family tyrosine kinase or Src-family tyrosine kinase.

8. The method of claim 7 , wherein said Abl-family tyrosine kinase inhibitor is imatinib mesylate or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug or derivative of imatinib mesylate, or the metabolite structure

9. The method of claim 8 , wherein said derivative of imatinib mesylate is STI-X.

10. The method of claim 1 , wherein said tyrosine kinase inhibitor is administered orally, nasally, buccally, sublingually, intravenously, transmucosally, rectally, topically, transdermally, subcutaneously, by inhalation, or intrathecally.

11. The method of claim 1 , wherein said viral infection is caused by a Vaccinia virus, a variola virus, a JC virus, a BK virus, a herpes virus, or a human immunodeficiency virus.

12. The method of claim 1 , wherein said bacterial infection is caused by Helicobacter pylori, Listeria monocytogenes, Shigella flexneri , or Mycobacterium tuberculosis.

13. The method of claim 1 , wherein said viral infection is caused by a Vaccinia virus, a variola virus, a polyoma virus, a Herpes virus, a cytomegalovirus (CMV), or a human immunodeficiency virus.

14. The method of claim 1 , wherein said tyrosine kinase inhibitor is an Abl-family tyrosine kinase inhibitor.

15. The method of claim 14 , wherein said Abl-family tyrosine kinase inhibitor is imatinib mesylate or STI-X.

16. The method of claim 3 , wherein said bacterial infection is caused by Helicobacter pylori, Listeria monocytogenes, Shigella flexneri , or Mycobacterium tuberculosis.

17. The method of claim 16 , wherein said tyrosine kinase inhibitor inhibits an Abl-family tyrosine kinase.

18. The method of claim 17 , wherein said Abl-family tyrosine kinase inhibitor is imatinib mesylate or STI-X.